Chemistry:Perfluorohexyloctane
Perfluorohexyloctane (branded as Evotears, Miebo,[lower-alpha 1] and Novatears, among others) is a medication used for the treatment of dry eye disease.[1] It is a semifluorinated alkane.[1]
Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears,[2] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo.[1][3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4]
Medical uses
Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.[1][5][6]
Availability
Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries,[7] costing around NZ$34.00, A$30, and €30 for a one-month supply.
In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required. Perfluorohexyloctane (also under the brand name Miebo) was approved by Health Canada in September 2024[8].
See also
Notes and references
- ↑ 1.0 1.1 1.2 1.3 Cite error: Invalid
<ref>tag; no text was provided for refs namedMiebo FDA label - ↑ "URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement" (Press release). Retrieved 2024-02-15.
- ↑ "Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease" (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.
- ↑ (PDF) New Drug Therapy Approvals 2023 (Report). January 2024. https://www.fda.gov/media/175253/download. Retrieved 9 January 2024.
- ↑ "Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent". The Ocular Surface 30: 254–262. October 2023. doi:10.1016/j.jtos.2023.10.001. PMID 37813152.
- ↑ "A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution". The American Journal of Managed Care 29 (14 Suppl): S251–S259. November 2023. doi:10.37765/ajmc.2023.89464. PMID 37930231.
- ↑ "In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On" (Press release). Retrieved 2024-02-15.
- ↑ "Regulatory Decision Summary for Miebo". September 4, 2024. https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1732548590090.
Further reading
- "MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease". Annals of Medicine and Surgery (2012) 86 (9): 5292–5298. September 2024. doi:10.1097/MS9.0000000000002322. PMID 39239035.
 |  |
